EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma.
Dihydroxyphenylalanine
Fluorodeoxyglucose
Medullary thyroid carcinoma
PET/CT
Somatostatin
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
06
07
2019
accepted:
22
07
2019
pubmed:
5
9
2019
medline:
15
5
2021
entrez:
5
9
2019
Statut:
ppublish
Résumé
Medullary thyroid carcinoma (MTC) is a malignant tumour derived from the para-follicular thyroid C cells. It may occur in sporadic or hereditary forms and surgery represent the primary cure. Ultrasound examination and, in selected cases, cross-sectional anatomic imaging procedures, are adopted to stage the disease before primary surgery while different anatomic/morphologic and functional/molecular imaging procedures can be adopted in detecting persistent/recurrent disease. Positron emitting radiopharmaceuticals including fluorine-18 fluorodeoxyglucose ( This practice guideline from the Thyroid Committee of the European Association of Nuclear Medicine (EANM), with involvement of external experts, provides recommendations based on updated literature's evidences. The purpose of this practice guideline is to assist imaging specialists and clinicians in recommending, performing and interpreting the results of PET/CT with various radiopharmaceuticals in patients with MTC.
Sections du résumé
BACKGROUND
Medullary thyroid carcinoma (MTC) is a malignant tumour derived from the para-follicular thyroid C cells. It may occur in sporadic or hereditary forms and surgery represent the primary cure.
METHODS
Ultrasound examination and, in selected cases, cross-sectional anatomic imaging procedures, are adopted to stage the disease before primary surgery while different anatomic/morphologic and functional/molecular imaging procedures can be adopted in detecting persistent/recurrent disease. Positron emitting radiopharmaceuticals including fluorine-18 fluorodeoxyglucose (
CONCLUSIONS
This practice guideline from the Thyroid Committee of the European Association of Nuclear Medicine (EANM), with involvement of external experts, provides recommendations based on updated literature's evidences. The purpose of this practice guideline is to assist imaging specialists and clinicians in recommending, performing and interpreting the results of PET/CT with various radiopharmaceuticals in patients with MTC.
Identifiants
pubmed: 31482429
doi: 10.1007/s00259-019-04458-6
pii: 10.1007/s00259-019-04458-6
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
61-77Commentaires et corrections
Type : CommentIn
Type : CommentIn
Références
Clin Endocrinol (Oxf). 1998 Mar;48(3):265-73
pubmed: 9578814
Endocrine. 2012 Dec;42(3):535-45
pubmed: 22527889
Eur Radiol. 2009 Jun;19(6):1425-34
pubmed: 19156423
Acad Radiol. 2012 Oct;19(10):1290-9
pubmed: 22819076
Hormones (Athens). 2013 Jul-Sep;12(3):327-33
pubmed: 24121375
Nucl Med Commun. 2017 Jul;38(7):636-641
pubmed: 28562377
Endocrinology. 2004 Dec;145(12):5465-70
pubmed: 15459123
J Nucl Med. 1988 Jan;29(1):33-8
pubmed: 2826723
Clin Endocrinol (Oxf). 2004 Sep;61(3):299-310
pubmed: 15355445
Rev Esp Med Nucl Imagen Mol. 2012 Sep;31(5):261-6
pubmed: 23067528
Cancer. 1984 Aug 15;54(4):657-62
pubmed: 6378353
Am J Nucl Med Mol Imaging. 2013 Dec 15;4(1):39-52
pubmed: 24380044
Nucl Med Commun. 2012 Jul;33(7):775-9
pubmed: 22546877
Biomed Pharmacother. 2008 Mar;62(3):139-46
pubmed: 17892924
Recent Results Cancer Res. 2013;194:385-93
pubmed: 22918771
J Exp Clin Cancer Res. 2014 Oct 25;33:87
pubmed: 25344474
Clin Cancer Res. 2010 Nov 1;16(21):5260-8
pubmed: 20847059
J Clin Endocrinol Metab. 2007 Nov;92(11):4185-90
pubmed: 17726071
Endokrynol Pol. 2010 Sep-Oct;61(5):507-11
pubmed: 21049467
Nature. 1993 Jun 3;363(6428):458-60
pubmed: 8099202
Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1486-90
pubmed: 27118126
J Clin Endocrinol Metab. 2007 Dec;92(12):4590-7
pubmed: 17878252
Hell J Nucl Med. 2015 Jan-Apr;18(1):19-24
pubmed: 25679074
Eur J Surg Oncol. 2008 May;34(5):581-6
pubmed: 17892923
J Clin Oncol. 2010 May 10;28(14):2323-30
pubmed: 20368568
Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1995-2001
pubmed: 26173620
J Nucl Med. 2007 Apr;48(4):501-7
pubmed: 17401085
Nucl Med Commun. 2013 Feb;34(2):185-6
pubmed: 23111381
J Clin Endocrinol Metab. 2001 Feb;86(2):895-902
pubmed: 11158063
Clin Chem Lab Med. 2015 Sep 1;53(10):1507-14
pubmed: 25781697
Nucl Med Rev Cent East Eur. 2011;14(1):16-20
pubmed: 21751167
Int J Endocrinol Metab. 2013 Oct 01;11(4):e8156
pubmed: 24719630
Anticancer Res. 2014 Nov;34(11):6647-54
pubmed: 25368270
Henry Ford Hosp Med J. 1989;37(3-4):175-7
pubmed: 2576958
J Clin Endocrinol Metab. 1997 Jan;82(1):42-7
pubmed: 8989230
J Nucl Med. 2016 Oct;57(10):1505-1511
pubmed: 27230928
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1588-1601
pubmed: 28547177
J Nucl Med. 2011 Dec;52(12):1855-63
pubmed: 22052128
Int J Mol Imaging. 2012;2012:324686
pubmed: 22852077
Endocr J. 2010;57(12):1045-54
pubmed: 20978365
J Clin Endocrinol Metab. 1993 Jun;76(6):1413-7
pubmed: 8501144
J Nucl Med. 2018 May;59(5):756-761
pubmed: 29025983
Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2004-2013
pubmed: 28646462
Head Neck. 2014 Aug;36(8):1216-23
pubmed: 23955938
Nucl Med Commun. 2011 Dec;32(12):1162-8
pubmed: 21946617
Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1695-1701
pubmed: 28429044
J Clin Endocrinol Metab. 2012 Oct;97(10):E2031-5
pubmed: 22865907
Nucl Med Commun. 2010 Jun;31(6):567-75
pubmed: 20335822
Diagn Cytopathol. 2016 Jan;44(1):45-51
pubmed: 26481456
Eur J Nucl Med Mol Imaging. 2013 Feb;40(3):364-72
pubmed: 23151915
Eur Arch Otorhinolaryngol. 2013 May;270(6):1783-7
pubmed: 23053387
Clin Endocrinol (Oxf). 1996 Mar;44(3):249-57
pubmed: 8729519
Mol Imaging Biol. 2010 Oct;12(5):547-53
pubmed: 19949985
Nucl Med Commun. 2013 Dec;34(12):1141-9
pubmed: 24128899
Eur J Surg Oncol. 2010 Apr;36(4):414-21
pubmed: 20100647
Thyroid. 2012 Jun;22(6):654-5
pubmed: 22568397
Minerva Endocrinol. 2008 Jun;33(2):67-73
pubmed: 18388854
World J Surg. 2002 Jan;26(1):22-8
pubmed: 11898029
Thyroid. 2015 Jun;25(6):567-610
pubmed: 25810047
Endocr Relat Cancer. 2015 Jun;22(3):R157-64
pubmed: 25934688
Clin Nucl Med. 2001 Aug;26(8):683-8
pubmed: 11452174
Clin Endocrinol (Oxf). 2015 Feb;82(2):280-5
pubmed: 25047365
Nucl Med Commun. 2015 Mar;36(3):242-50
pubmed: 25369749
Nature. 1994 Jan 27;367(6461):375-6
pubmed: 7906866
J Natl Compr Canc Netw. 2010 May;8(5):549-56
pubmed: 20495084
Thyroid. 2010 May;20(5):527-33
pubmed: 20450432
Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2159-2169
pubmed: 29766245
J Nucl Med. 1996 Jun;37(6):912-6
pubmed: 8683310
Hormones (Athens). 2017 Oct;16(4):362-372
pubmed: 29518756
Ann Nucl Med. 2018 Jan;32(1):7-15
pubmed: 28986764
Am J Clin Pathol. 2015 Jun;143(6):768-77
pubmed: 25972318
Nucl Med Commun. 2012 Feb;33(2):179-84
pubmed: 22083098
Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1027-33
pubmed: 26497699
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
J Clin Endocrinol Metab. 2013 Feb;98(2):E364-9
pubmed: 23264394
Clin Endocrinol (Oxf). 1995 Jan;42(1):31-7
pubmed: 7889629